Development of diagnostic method using a fluorescent labeled glucose in urological cancer

Development of diagnostic method using a fluorescent labeled glucose in urological cancer - Development of diagnostic method using a fluorescent labeled glucose in urological cancer

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010865

Enrollment

100

Registered

2013-08-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urinary Bladder Cancer, Prostate Cancer

Interventions

fluorescently labeled glucose test

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Patients with urinary bladder cancer who will receive endoscopic resection of bladder tumor, or patients who are suspicious for prostate cancer (PSA level >= 4).

Exclusion criteria

Exclusion criteria: Patients who did not obtain written informed consent.

Design outcomes

Secondary

Measure	Time frame
Correlation between fluorescence degree and malignant potential of urinary bladder cancer and prostate cancer.	—

Primary

Measure	Time frame
Confirmation of fluorescence labeled glucose taken in only cancer cells in urinary bladder cancer and prostate cancer.	—

Countries

Japan

Contacts

Public ContactShingo Hatakeyama

Hirosaki University Hospital Urology

shingorilla2@gmail.com+81172395091

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026